Innovation in der Nuklearmedizin für eine bessere Lebensqualität von Patienten
Unsere Tätigkeit
Unser Ziel: Innovationen für Patienten.
Advanced Accelerator Applications entwickelt eine Reihe von nuklearmedizinischen theragnostischen Kombinationen für onkologische Indikationen.
Unsere Produkte umfassen Radiopharmaka zur molekularen Bildgebung mit Positronenemissionstomografie (PET) oder Einzelphotonen-Emissionscomputertomographie (SPECT).
Klinischen Studien
Im Rahmen unseres Entwicklungsprozesses werden unsere Radioligandenprodukte in klinischen Studien beurteilt, um neue und bessere Möglichkeiten zur Diagnose und Behandlung von Krankheiten zu finden.
April 23, 2020
Starting May 11, 2020, Accelerators Applications (AAA), a Novartis Company, will introduce company-wide a flexible working model that invites associates, country-by-country, to return to the office and restart on-site field activities, when possible and appropriate, based on the respective local situation and risk assessment. This is applicable to all countries and markets.
The health, wellbeing and safety of our associates remains paramount. This means each country leadership team, in accordance with local authorities, will decide when and how to loosen or tighten restrictions and voluntarily offer associates the opportunity to return.
Advanced Accelerator Applications fully recognizes that some associates are eager to return to the office while others may prefer to continue to work from home. So the decision to return is for each associate to make in accordance with their manager. No one should feel forced or pressured to return. To help associates, the local leadership team will provide local guidance and support. Advanced Accelerator Applications and Novartis continue to provide additional resources like coaching and learning tools – irrespective of place of work.
March 27, 2020
As the coronavirus (COVID-19) situation continues to evolve, our primary concern at Advanced Accelerators Applications (AAA), a Novartis Company, remains the health and safety of our associates and patients globally. With that in mind, this week Advanced Accelerator Applications announced a range of additional measures to protect and support our associates around the world.
Announced this week, Advanced Accelerator Applications has extended its guidance for all Advanced Accelerator Applications associates within Europe, US and Canada to work from home until May 1, 2020, with the exception of those working in laboratories, manufacturing sites and in the field. We continue to assess the situation and adapt accordingly. Advanced Accelerator Applications is also taking steps to support the health and wellbeing of our associates globally as they adapt to new working dynamics and family commitments as a result of the COVID-19 pandemic.
Advanced Accelerator Applications remains responsive to any developments regarding coronavirus and will take all necessary steps to protect its associates and patients as the situation evolves.
As before, we will continue to deliver our medicines to patients around the world and we do not anticipate supply chain disruption at this time.
March 16, 2020
As the Coronavirus (COVID-19) continues to spread globally, our primary concern at Advanced Accelerators Applications (AAA), a Novartis Company, remains the health and safety of our associates and patients globally, and it is important that we protect them.
With that in mind, effective Monday, March 16 2020, all Advanced Accelerator Applications associates within Europe, US and Canada are requested to work from home, with the exception of those working in laboratories, manufacturing sites, in the field, or in other essential functions. This measure is valid for three weeks until April 3, 2020. We will continuously assess the situation and adapt accordingly.
Some governments around the world are providing local guidance that is stricter than this global guidance. In those cases, the local guidance takes precedence.
Given the nature of some of the work undertaken at Advanced Accelerator Applications, it is not possible for everyone to work remotely. By reducing the number of associates visiting our sites, we can protect those employees who cannot work offsite.
In addition to the measures above, Advanced Accelerator Applications has updated its general international travel restriction. All international business travel requires approval from an executive level manager, in alignment with local authorities.
Advanced Accelerator Applications remains responsive to any developments regarding coronavirus and will take all necessary steps to protect its associates and patients as the situation evolves.
As before, we will continue to deliver our medicines to patients around the world and we do not anticipate supply chain disruption at this time.
Where required, we have enacted mitigation plans to ensure ongoing drug supply to depots for our clinical studies, and we are working closely with the authorities on dispensing to trial participants.
March 12, 2020
As Advanced Accelerators Applications (AAA), a Novartis Company, continues to closely monitor the coronavirus situation, our primary concern is the health and safety of our associates and patients globally. We will continue to deliver our medicines to patients around the world and we do not anticipate supply chain disruption at this time.
Advanced Accelerator Applications has also put the following measures in place:
- We are updating travel advisories in line with warning levels provided by the US Centers for Disease Control and Prevention
- We have issued guidance on how our associates can protect themselves against coronavirus infection, and also updated travel restrictions for non-essential business travel worldwide
- Where required, we have enacted mitigation plans to ensure ongoing drug supply to depots for our clinical studies, and we are working closely with the authorities on dispensing to trial participants
Advanced Accelerator Applications remains responsive to any developments regarding coronavirus and will take all necessary steps to protect its associates and patients as the situation evolves.